U.S., Oct. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07221084) titled 'A Study to Assess Pharmacokinetics, Safety, and Tolerability of Atumelnant in Healthy Japanese and Caucasian Participants' on Oct. 22.
Brief Summary: The purpose of this study is to assess the PK profile, safety, and tolerability of atumelnant after single and multiple once daily (QD) oral doses in healthy Japanese and Caucasian adult participants.
Study Start Date: Oct., 2025
Study Type: INTERVENTIONAL
Condition:
Healthy Volunteers
Intervention:
DRUG: Atumelnant
Atumelnant, tablets, once daily by mouth
DRUG: Placebo
Placebo, tablets, once daily by mouth
Recruitment Status: RECRUITING
Sponsor: Crinetics Pharmaceuticals In...